March 27, 2026

Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma

Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precurso...

The ASCO Post

March 27, 2026

Recipients Named for the 2026 Pezcoller Foundation–AACR International Award

The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research will be presented to Douglas R. Lowy, MD, and John T. Schi...

The ASCO Post

March 26, 2026

AI As Collaborator in Cancer Research and in Clinical Care

Last October, the Cancer AI Alliance (CAIA) announced the launch of its collaborative artificial intelligence (AI) platform powered by federated learning to train AI models with millions of de-identif...

The ASCO Post

March 26, 2026

Roswell Park Faculty to Present at National Comprehensive Cancer Network 2026 Annual Conference

Clinical researchers from Roswell Park Comprehensive Cancer Center are among the experts invited to share insights and clinical best practices at the National Comprehensive Cancer Network (NCCN) 2026 Annual Conference March 27-29 in Orlando, Florida.

Roswell Park Comprehensive Cancer Center

March 24, 2026

Will Circulating Tumor DNA Help Predict HPV-Related Throat Cancer?

A Keck Medicine of USC head and neck surgeon discusses circulating HPV DNA as a biomarker that could help make more individualized treatment decisions.

Keck Medicine of USC

March 24, 2026

Stanford Names Leader for Drug Development and Precision Oncology

Vivek Subbiah, MD, has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. In thi...

The ASCO Post

March 24, 2026

Integrative Oncology Scholars Program

Applications are now being accepted for the 2026 Integrative Oncology Scholars Program and Integrative Oncology Fellows Program at the University of Michigan in Ann Arbor (https://sites.google.com/vie...

The ASCO Post

March 24, 2026

Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma

A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could...

The ASCO Post

March 24, 2026

How AI Is Already Having a Significant Impact on Cancer Care

Three education sessions presented during the 2025 ASCO Annual Meeting showcased how artificial intelligence (AI) is quickly transforming cancer care from clinical trial planning and ambient scribes t...

The ASCO Post

March 23, 2026

Dietary Influence on Leukemia and Lymphoma Progression

In 2015, LH, a 66-year-old female, was diagnosed with chronic lymphocytic leukemia (CLL), Rai stage 0. Untreated, the woman’s lymphocyte count rose from 5,000/mm3 to 16,000/mm3 in 6 years (doubling ti...

The ASCO Post